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The association between the development of 
metastasis and the risk of thrombotic com­
plications  has  been  documented  since  1865.   
Armand Trousseau was the first to establish a 
direct correlation between thrombophlebitis 
and the development of cancer (Trousseau, 
1865). A rather common complication and one 
of the leading causes of death in patients with 
cancer is the risk of developing thromboem­
bolic diseases (Kakkar and Williamson, 1999; 
Stein et al., 2006; Schiavetti et al., 2008). The 
incidence of thrombosis is high in adenocarci­
nomas such as ovarian, prostate, lung, and gas­
trointestinal carcinomas (Blom et al., 2006b), 
and it is particularly high (up to 57%) in pa­
tients suffering from pancreatic cancer (Sack   
et al., 1977; Blom et al., 2006a). In the latter 
case, thromboembolic diseases are the second 
most common cause of mortality, accounting 
for 44% of total deaths after cancer progression 
(Neoptolemos et al., 2001). The recurrence of 
thrombotic complications may also be the first 
manifestation of underlying malignant disease 
(Prandoni et al., 1992).
The pathogenesis of the thrombotic state in 
cancer is associated with the generation of a   
local and systemic hypercoagulable/thrombotic 
state that confers a growth advantage to tumor 
cells. It is now known that activation of the 
coagulation cascade and aggregation of blood 
platelets around cancer cells protects the cells 
from the different degradative pathways pres­
ent in the blood, and also facilitates dissemina­
tion of cancer cells to various sites of metastasis 
(Gasic et al., 1976; Sierko and Wojtukiewicz, 
2007). This supports a model in which the pres­
ence of tissue factor (TF), generation of throm­
bin, and activation of platelets favor the aggressive 
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Recent publications have demonstrated the presence of tissue factor (TF)–bearing mic-
roparticles (MPs) in the blood of patients suffering from cancer. However, whether these 
MPs are involved in thrombosis remains unknown. We show that pancreatic and lung 
cancer cells produce MPs that express active TF and P-selectin glycoprotein ligand 1 
(PSGL-1). Cancer cell–derived MPs aggregate platelets via a TF-dependent pathway. In vivo, 
cancer cell–derived MPs, but not their parent cells, infused into a living mouse accumulate 
at the site of injury and reduce tail bleeding time and the time to occlusion of venules and 
arterioles. This thrombotic state is also observed in mice developing tumors. In such mice, 
the amount of circulating platelet-, endothelial cell–, and cancer cell–derived MPs is 
increased. Endogenous cancer cell–derived MPs shed from the growing tumor are able to 
accumulate at the site of injury. Infusion of a blocking P-selectin antibody abolishes the 
thrombotic state observed after injection of MPs or in mice developing a tumor. Collec-
tively, our results indicate that cancer cell–derived MPs bearing PSGL-1 and TF play a key 
role in thrombus formation in vivo. Targeting these MPs could be of clinical interest in the 
prevention of thrombosis and to limit formation of metastasis in cancer patients.
© 2009 Thomas et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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biology of cancer. Nevertheless, the cause of this association 
remains unclear.
Different reports suggest a potential role for circulating 
microparticles (MPs) in the establishment of a thrombotic state 
in cancer (Kim et al., 2003; Del Conde et al., 2007; Tilley   
et al., 2008). MPs are defined as cell­derived membrane frag­
ments and range in size from 0.1 to 1 µm in diameter. They 
are characterized by their presence at the surface of negative 
phospholipid moieties that are essential for initiation of blood 
coagulation (Ghosh et al., 2008); they also bear at least one   
of the antigenic markers distinctive of the parent cell (Abid 
Hussein et al., 2003). Aggregated platelets, leukocytes, eryth­
rocytes, and endothelial lineages constitute the most impor­
tant sources of circulating MPs under many pathophysiological 
situations, including thrombosis, inflammation, and angiogen­
esis (Müller et al., 2003). Recent clinical studies have shown 
that the concentration of circulating TF­bearing MPs is sig­
nificantly greater in patients with cancer (Tilley et al., 2008), 
including patients with pancreatic cancer (Del Conde et al., 
2007; Hron et al., 2007; Tesselaar et al., 2007), suggesting that 
these MPs may be responsible for the thrombotic state associ­
ated with cancers. Meanwhile, the cellular origins of such MPs 
have not been determined (Hron et al., 2007; Zwicker et al., 
2007; Langer et al., 2008) and may include platelets (Hron   
et al., 2007; Tesselaar et al., 2007), cancer cells (Dvorak et al., 
1981), or monocytes (Falati et al., 2003; Myers et al., 2003; 
Vandendries et al., 2007). At their surface, platelet­derived 
MPs express activated integrins (e.g., IIb3 or v3) and   
receptors (i.e., GPVI and GPIb­IX­V) known to be involved 
in  thrombus  formation.  Monocyte­derived  MPs  that  have 
been isolated, labeled, and infused into a recipient mouse ac­
cumulate at the site of a laser­induced injury by binding to   
P­selectin expressed on activated platelets through P­selectin 
glycoprotein ligand 1 (PSGL­1; Falati et al., 2003; Vandendries 
et al., 2007). To date, no study has determined the role of 
cancer cell–derived MPs in thrombus formation in vivo.
In the present study, we hypothesize that cancer cell– 
derived MPs bearing PSGL­1 are involved in the development 
of a thrombotic state. We demonstrate that pancreatic cancer 
cells are able to produce MPs in vitro that express active TF 
and PSGL­1. We show that cancer cell–derived MPs circu­
late in the bloodstream and accumulate at the site of injury in 
a P­selectin–dependent manner in vivo. Finally, we observe 
that cancer cell–derived MPs, but not their parental cells, ac­
celerate thrombus formation in a mouse model of cancer.
RESULTS
Human and mouse pancreatic and lung cancer cell lines  
are able to shed MPs that express TF and PSGL-1 in vitro
To determine whether pancreatic or lung cancer cells could 
shed MPs, ultracentrifuged supernatants of human (SOJ­6) 
and mouse (Panc02) adenocarcinoma pancreatic cell lines or 
mouse Lewis lung carcinoma cancer cell lines (LLC1) were 
evaluated by flow cytometry. All cancer cell lines produced 
vesicles ranging in size from 0.4 to 1 µm in diameter, and these 
particles were able to bind annexin V (Fig. 1 A). Previous   
Figure 1.  Pancreatic and lung cancer cell lines shed MPs that  
express TF in vitro. (A) Flow cytometry analysis showing annexin V–FITC 
labeling of SOJ-6, Panc02, and LLC1 cell–derived MPs. Negative controls 
were realized without addition of calcium. (B) Immunofluorescence micros-
copy of cancer cells using an anti-TF antibody. (C) Western blot analysis of 
protein extracts from SOJ-6–derived MPs with a specific anti-TF antibody. 
All of the experiments were independently performed three times.JEM VOL. 206, August 31, 2009 
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reports have shown that TF is present on the surface of can­
cer cell lines (Haas et al., 2006; Khorana et al., 2007). Ac­
cordingly, we observed that SOJ­6, Panc02, and LLC1 cancer 
cells express TF on their surface by immunofluorescence 
(Fig. 1 B). TF was also detected by Western blotting of lysates 
obtained from pancreatic cancer cell–derived MPs (Fig. 1 C). 
Identical results were obtained with all other pancreatic adeno­
carcinoma  (BxPC­3)  and  carcinoma  (MiaPaCa­2,  PANC­1, 
and LLC1) cell lines studied. Monocyte­derived MPs have 
been shown to express PSGL­1 (Falati et al., 2003; Myers et al., 
2003). Double labeling with annexin V as a positive control 
revealed that Panc02 and LLC1 cancer cells (Fig. 2 A), as well 
as Panc02­ and LLC1­derived MPs (Fig. 2 B), express PSGL­1 
but not P­selectin (not depicted) on their surface. PSGL­1 
was also detected by Western blotting in lysates obtained 
from pancreatic cancer cell– and monocyte­derived MPs 
(Fig. 2 C). In contrast, no signal was detected by flow cytom­
etry analysis or Western blotting when mouse fibroblast–derived 
MPs (L929 cell lines) were studied. We conclude that pan­
creatic and lung cancer cells can shed MPs that constitutively 
express active TF and PSGL­1.
Cancer cell–derived MPs, but not their parental cells, 
modulate thrombus formation in vivo
We have previously described the kinetics of thrombus forma­
tion in mice after an injury induced by topical application of 
an FeCl3 solution (Dubois et al., 2006b). To determine the 
involvement of MPs in thrombus formation in vivo, experi­
ments we performed using a fibered fluorescent microscope that 
allows for real­time in vivo imaging after excitation at 660 nm. 
We examined thrombus formation induced by exposure 
of the adventitial surface of the mouse mesenteric vessels to 
10% FeCl3 for 5 min. Under these conditions, platelets began 
to accumulate in injured vessels between 5 and 15 min after 
FeCl3 exposure (Fig. 3 A). Only three out of the eight wild­
type mice studied formed occlusive thrombi during the   
35­min experiment (Fig. 3 B). When Panc02 cancer cell–derived 
MPs (0.2 µg/g/mouse corresponding to 18,000 MPs/g/mouse) 
were infused into the bloodstream 5 min before topical appli­
cation of FeCl3, platelets began to accumulate 1–5 min after 
induction of the injury, leading to occlusion of the arterioles 
between 3 and 10 min after injury (Fig. 3 A). The median 
time to occlusion of the arteriole in this condition was 6 min 
(P < 0.01; Fig. 3 B). Similar results were observed after infu­
sion of LLC1­derived MPs (0.08 µg/g/mouse, corresponding 
to 18,000 MPs/g/mouse), with a median time to occlusion of 
the arteriole of 12 min (P < 0.05; Fig. 3 B). The median time 
to  arteriole  occlusion  was  significantly  shorter  than  the 
median time to occlusion observed without infusion of 
MPs (P < 0.05). These results indicate that infusion of cancer 
Figure 2.  Pancreatic and lung cancer cell–derived MPs express 
PSGL-1. (A) Immunofluorescence microscopy of SOJ-6, Panc02, and LLC1 
cells with an antibody directed against PSGL-1 and an Alexa Fluor 488–
conjugated secondary antibody. Incubation with the secondary antibody 
alone served as a negative control. (B) Flow cytometric analysis of J774 
(C+), L929 (C), Panc02-, and LLC1-derived MPs labeled both with an-
nexin V–FITC and with an anti–PSGL-1 PE-conjugated antibody. PSGL-1+ 
MPs are represented by the black histogram. Negative controls were ob-
tained by excluding calcium from the annexin V labeling and in the pres-
ence of an irrelevant PE-conjugated IgG (gray histogram). (C) Western 
blot analysis of Panc02-derived MPs (Panc02 MPs) and J774 (C+) and 
L929 (C) cells with a specific anti–PSGL-1 antibody. All of the experi-
ments were independently performed three times.
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Figure 3.  Cancer cell–derived MPs accelerate thrombus formation in vivo. Thrombus formation was assessed after infusion of Alexa Fluor 660–
conjugated anti-CD41 antibody into wild-type mice in the presence of Panc02-derived MPs (MPs Panc02, 0.2 µg of MP-associated proteins/g/mouse), 
LLC1-derived MPs (MPs LLC1, 0.08 µg of MP-associated proteins/g/mouse), or Panc02 cells (Cells Panc02, 5,000 cells/g/mouse) or LLC1 cells (Cells LLC1, 
5,000 cells/g/mouse). Injury of the mesenteric vessels was induced with 10% FeCl3 for 5 min. (A) Representative composite images of fluorescence depicting JEM VOL. 206, August 31, 2009 
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cell–derived MPs affected the kinetics of thrombus formation. 
To determine whether cancer cells may also be involved in 
thrombus formation, we determined the time to occlusion in 
arterioles after infusion of cancer cells (5,000 cells/g/mouse, 
equivalent to the maximum concentration of cells that may be 
infused without altering blood flow; not depicted; Fig. 3 A). 
In this condition, no statistical difference was found in com­
parison with the kinetics observed when wild­type mice were 
injured. Indeed, platelet accumulation was detected between 
5 and 10 min after injury. Only three out of seven mice stud­
ied after infusion of Panc02 cells and only one out of eight 
mice studied after infusion of LLC1 cells formed occlusive 
thrombi (Fig. 3 B). To confirm the involvement of cancer 
cell–derived MPs in thrombus formation, tail bleeding time 
experiments were performed as previously described (Panicot­
Dubois et al., 2007). After injection with Panc02­ and LLC1­
derived MPs, the median tail bleeding time observed in 
wild­type mice was 63 s (n = 8) and 79 s (n = 7), respectively. 
These values were significantly lower (P < 0.01) than the 
bleeding times (close to 150 s) obtained for wild­type mice 
that were not infused with cells or MPs (n = 13), wild­type 
mice infused with Panc02 cells (n = 8), or wild­type mice in­
fused with LLC1 cells (n = 8; Fig. 3 C). We next determined 
the number of MPs sufficient enough to affect kinetics of 
thrombosis. We observed that an amount as low as 0.2 ng/g/
mouse of cancer cell–derived MPs significantly accelerated ki­
netics of thrombosis in vivo in our model (Fig. 3 D). Collec­
tively, these results indicate that infusion of cancer cell–derived 
MPs, but not infusion of their parental cells, accelerates throm­
bus growth in vivo, suggesting that cancer cell–derived MPs 
may participate in thrombus formation.
To determine whether cancer cell–derived MPs accu­
mulate at the site of FeCl3­induced injury in vivo, MPs were 
isolated, labeled with the DiD fluorochrome, and infused 
into a recipient mouse. First, we determined the half­life of 
exogenous MPs in the blood circulation of healthy mice 
(Fig. 4 A). The results show that 50% of exogenous MPs 
were eliminated from the blood circulation in <15 min, con­
firming the results previously described for erythrocyte­
derived MPs infused into the rat (Willekens et al., 2005). 
After infusion of exogenous MPs and induction of a chemi­
cal injury to mesenteric arterioles, a fluorescent signal corre­
sponding to DiD­labeled MPs was detected (Fig. 4 B). This 
accumulation of cancer cell–derived MPs at the site of in­
jury was further confirmed by intravital microscopy (Dubois 
et al., 2007; Panicot­Dubois et al., 2007). Using such a system, 
we simultaneously imaged DiO­labeled cancer­derived MPs 
(0.2 µg/g/mouse, corresponding to 18,000 MPs/g/mouse) 
and DiD­labeled cancer cells (5,000 Panc02 cells/g/mouse) 
infused into the bloodstream of a recipient mouse. Both 
cancer cell–derived MPs and cancer cells were detected cir­
culating in the blood (Fig. 4 C). However, only cancer cell–
derived MPs were found to accumulate at the site of the 
FeCl3­induced injury. 8 min after injury, the number of exog­
enous MPs accumulating at the site of injury increased, indi­
cating that thrombus­associated MPs remained in the animal 
for a longer time period than did circulating MPs (Fig. 4 C). 
We conclude that cancer cell–derived MPs, but not their 
parental cells, accumulate at the site of injury in vivo and 
accelerate thrombus growth.
Characterization of a thrombotic state in mice developing 
ectopic tumors
Next, we created a mouse model of cancer induced by subcu­
taneous injection of pancreatic (Panc02) or lung cancer (LLC1) 
cells. 5 wk after induction of the ectopic tumor, the number 
of endogenous circulating MPs in both healthy mice and mice 
developing tumors were compared by flow cytometry analy­
sis. To characterize the cellular origin of MPs, we first labeled 
MPs using antibodies specific for platelets (CD41+), erythro­
cytes (TER 119+), leukocytes (CD45+), cells likely of endo­
thelial origin (CD31+CD41), and cancer cells (MUC­1+). The 
data are presented in Table I (see also Fig. S1). As expected, 
the number of endogenous circulating annexin V+ MPs was 
significantly increased in mice developing tumors in compari­
son with control mice (median = 9,383 MPs/µl and 10,018 
MPs/µl  of  plasma  for  Panc02­  and  LLC1­induced­tumor 
mice, respectively, and 8,951 MPs/µl of plasma in control 
mice; P < 0.05). The amount of platelet­ and endothelial cell–
derived MPs was significantly increased in mice developing 
tumors in comparison with control mice. However, neither 
the  number  of  leukocyte­derived  circulating  MPs  nor  the 
quantity of endogenous erythrocyte­derived MPs increased in 
comparison with the control. We also addressed the presence 
of  endogenous  circulating  cancer  cell–derived  MPs  using 
Muc­1, a protein that is highly expressed in various epithelial 
cancers. As expected, the amount of Muc­1–bearing MPs was 
significantly increased in tumor­induced mice in comparison 
with healthy mice. We also detected MPs bearing the carbo­
hydrate CA19­9, which is highly expressed in lung and pan­
creatic cancers. Of note, this antigen was only present on MPs 
in blood obtained from Panc02­ and LLC1­tumor­induced 
thrombus formation of labeled platelet accumulation (white) on mesenteric vessels (Pre, before injury). (B) Time to vessel occlusion reported in minutes 
for mesenteric arterioles in wild-type mice (n = 10 thrombi in 10 mice), wild-type mice infused with Panc02-derived MPs (n = 10 thrombi in 7 mice), or 
with LLC1-derived MPs (n = 6 thrombi in 6 mice), Panc02 cells (n = 7 thrombi in 7 mice), or LLC1 cells (n = 8 thrombi in 8 mice). (C). Bleeding time in sec-
onds determined in wild-type mice (n = 13 mice), wild-type mice infused with Panc02-derived MPs (n = 8 mice), or with LLC1-derived MPs (n = 7 mice), 
Panc02 cells (n = 8 mice), or LLC1 cells (n = 8 mice). (D) Times to arteriole occlusion were observed in wild-type mice (n = 10 thrombi in 10 mice) and in 
wild-type mice infused with different concentrations of Panc02-derived MPs (MPs 0.02 ng/g/mouse, n = 7 thrombi in 6 mice; MPs 0.2 ng/g mouse, n = 7 
thrombi in 7 mice; and MPs 200 ng/g mouse, n = 10 thrombi in 9 mice). Horizontal bars indicate median values. Experiments were independently per-
formed 10 times (A and B) and at least six times (C and D). **, P < 0.01; *, P < 0.05.
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and venules of control and tumor­bearing mice (Fig. 5 B). 
A significant decrease in the time to occlusion of the arterioles 
(P < 0.05; Fig. 5 C) and venules (P < 0.05; Fig. 5 D) was ob­
served in mice developing tumors (a median time to occlu­
sion of 8 and 15 min in arterioles and 13 and 8 min in venules 
in mice developing Panc02­ and LLC1­induced tumors, re­
spectively) in comparison with control mice (median time > 35 
and 18 min in arterioles and venules, respectively). Interest­
ingly, the tail bleeding time and time to occlusion of arteri­
oles and venules were similar in mice developing tumors 
(median volume = 239 mm3) and mice for which Panc02­
derived MPs were infused into the circulation (compare   
Fig. 3 B with 5 C and Fig. 3 C with 5 A). Furthermore, we 
did not observe any linear correlation between the volume of 
the tumor and the bleeding time (Fig. 5 E). Our results indi­
cate that the presence of an ectopic tumor in mice increases 
the quantity of MPs present in the bloodstream and acceler­
ates thrombus formation, as compared with healthy mice.
mice (Table I). Because we have previously observed that 
Panc02­ and LLC1­derived MPs express PSGL­1 on their sur­
face (Fig. 2) and because the quantity of leukocyte­derived 
MPs, which also bear PSGL­1, was not increased in tumor­in­
duced mice in comparison with control mice, we determined 
the quantity of circulating PSGL­1–bearing MPs in the differ­
ent populations of mice. The number of MPs bearing PSGL­1 
was significantly increased in mice developing tumors in com­
parison with healthy mice. Collectively, our results indicate 
that the elevation of endogenous cell–derived MPs positive for 
annexin V results from a selective increase in MPs originating 
from platelets, endothelial cells, and tumor cells.
Tail bleeding times were significantly reduced in mice 
developing a tumor (median times for mice that received 
Panc02 or LLC1 cancer cells were 70 and 78 s, respectively) 
in comparison with mice that did not (median time = 150 s; 
P < 0.01; Fig. 5 A). We determined the kinetics of thrombus 
formation after FeCl3 injury to both the mesenteric arterioles 
Figure 4.  Cancer cell–derived MPs accumulate at the site of injury in mice. (A) Half-life of DiO-labeled Panc02-derived MPs in the blood circula-
tion of a healthy mouse (n = 4 mice, performed independently) reported as the mean ± SD. (B) Imaging of DiD-labeled Panc02-derived MPs using fibered 
fluorescence microscopy. Panc02-derived MPs were labeled with DiD (left) before infusion into the blood circulation of a living mouse. Although no fluo-
rescent signal was detected in the microcirculation before injury (middle), MPs were detected accumulating at the site of FeCl3-induced injury (right). 
Images are representative of six injuries performed in three mice, independently. (C) Intravital videomicroscopy visualization of mesenteric vessels. DiO-
labeled MPs (depicted in green; 0.2 µg of MP-associated proteins/g/mouse) and their DiD-labeled parental cells (depicted in red; 5,000 cells/g/mouse) 
were simultaneously infused into a recipient mouse. Circulating MPs and cells were detected in the microcirculation before injury (second from left). Note 
that no fluorescent signal was detected before infusion of MPs and cells (left). The experiment was independently performed three times in three mice.JEM VOL. 206, August 31, 2009 
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transfected Panc02 cells with the pEGFP­N1 vector encoding 
GFP (Fig. 6 B). 5 wk after subcutaneous injection of Panc02 
cells overexpressing GFP, the presence and accumulation of a 
fluorescent signal before and after injury induced by a dye laser 
(Dubois et al., 2006a; Dubois et al., 2007) were detected in 
the cremaster microcirculation using the intravital microscope. 
Particles were observed, ranging in size from 0.4 (the mini­
mum size we were able to detect using our system) to 1 µm 
(the maximum size measured for detected particles), that were 
likely endogenous MPs circulating in the blood circulation 
(Fig. 6 C) and accumulating at the site of injury in both ve­
nules (Fig. 6 D, left) and arterioles (Fig. 6 D, right). Together 
with our previous results showing that Panc02­derived MPs 
but not Panc02 cells accumulate at the site of injury, we con­
clude that Panc02­derived MPs shed from a growing tumor 
circulate in the bloodstream and participate in thrombus for­
mation in mice.
Endogenous cancer-derived MPs accumulate at the site  
of injury by binding to P-selectin and accelerate thrombus 
growth in a TF-dependent pathway
The thrombotic effects of cancer cell–derived MPs on tail 
bleeding time (Fig. 7 A) and time to occlusion of arterioles 
(Fig. 7 B) and venules (Fig. 7 C) were significantly decreased 
Endogenous cancer-derived MPs accumulate at the site  
of thrombus formation in vivo
To determine if cancer cells and/or MPs shed during tumor 
growth could participate and influence thrombus formation in 
vivo, an ectopic tumor was induced by injection of Panc02 
cells labeled with quantum dots (Qdots). Using this com­
pound, we were able to detect fluorescence in vitro for more 
than a week in cultured cells and in MPs shed from the cells 
(unpublished data). 1 wk after injection of Qdot­labeled cells, 
FeCl3 injury was administered to the mesentery of the mouse. 
The presence of Panc02 cells and/or MPs at the site of injec­
tion, in the circulation, and at the site of injury was followed 
by in vivo imaging. As expected, when Qdots alone were in­
jected into mice, a fluorescent signal was detected 1 wk later 
only at the site of injection. In contrast, Qdot­labeled cells 
and/or MPs were detected at the site of injection and in the 
circulation, and also accumulated at the site of injury (Fig. 6 A). 
These results indicate that in mice developing ectopic tumors, 
cancer cells and/or cancer­derived MPs may reach the blood­
stream and accumulate at the site of injury, suggesting that 
these MPs may influence the kinetics of thrombus growth. To 
discriminate between Panc02 cells and endogenous Panc02­
derived MPs (produced by the tumor in contrast with MPs 
prepared in vitro and infused into the bloodstream), we stably 
Table I.  Number and cellular origins of MPs (×106/liter1 plasma) in healthy and cancer mice
MP origins Controls (n = 8) Pancreatic cancer (n = 8) Lung cancer (n = 7) p-valuea p-valueb
×106/liter1 plasma ×106/liter1 plasma ×106/liter1 plasma
Total (annexin V+)          
  Median 8,951 9,383 10,018 0.024 0.047
  Range 5,994–14,714 5,536–14,794 5,048–16,442
Platelet (CD41+)
  Median 2,294 3096 3,024 0.035 0.014
  Range 1,724–3,216 1,636–5,476 770–8,784
Erythrocyte (TER 119+)
  Median 1,410 694 828 0.149 0.242
  Range 250–4,672 288–2,712 478–2,480
Leukocyte (CD45+)
  Median 346 251 722 0.209 0.424
  Range 74–1,032 130–888 68–2,206
Endothelial cell (CD31+CD41)
  Median 135 275 164 0.001 0.014
  Range 108–330 150–336 92–296
MUC-1+
  Median 117 1089 1,492 0.003 0.003
  Range 0–7,424 0–15,468 98–4,786
CA19.9+
  Median 0 264 127 0.001 0.003
  Range 0 0–6,852 0–2,428 (n = 6)
Annexin V+ PSGL-1+
  Median 146 293 234 0.004 0.006
  Range 76–376 74–522 134–550
aDifferences between mice developing a pancreatic cancer and healthy mice.
bDifferences between mice developing a lung cancer and healthy mice.1920 A THROMBOTIC ROLE FOR CANCER MICROPARTICLES | Thomas et al.
TF was present in a decrypted (active) form on the surface of 
cancer cells and MPs, the activity of TF present on SOJ­6, 
Panc02, and LLC1 cells, as well as MPs, was determined. 
when proteins at the surface of MPs were stripped by trypsin 
before infusion into the recipient mouse. Cancer cells and MPs 
express TF on their surfaces (Fig. 1). To determine whether 
Figure 5.  Characterization of a thrombotic state in mice developing tumors. Kinetics of thrombosis in wild-type mice or in mice developing 
Panc02-derived (Cancer Panc02) or LLC1-derived (Cancer LLC1) tumors. (A) Bleeding times were determined in wild-type mice (n = 13 mice), mice devel-
oping a Panc02 tumor (n = 11 mice), or mice developing an LLC1 tumor (n = 6 mice). (B) Thrombus formation was studied after infusion of Alexa Fluor 
660–conjugated anti-CD41 Fab fragment and Syto 62 in wild-type mice and in mice developing tumors. Injury was induced in mesenteric vessels by topi-
cal application of 10% FeCl3 for 5 min. Representative fluorescence images depicting the kinetics of thrombus formation of labeled platelet accumulation 
(white) on mesenteric arterioles (Pre, before injury). (C and D) Time to vessel occlusion reported in minutes for mesenteric arterioles (n = 13, 7, and 6 
thrombi for WT, Cancer Panc02, and Cancer LLC1, respectively; C) and venules (n = 13, 11, and 6 thrombi for WT, Cancer Panc02, and Cancer LLC1, respec-
tively; D). One injury was performed per mouse. (E) Bleeding times (in seconds) in function of the tumor volume (in mm3) in Panc02 tumor–bearing mice 
(n = 11). The linear coefficient of determination value is represented by R2. Horizontal bars in A, C, and D indicate median values. Experiments were inde-
pendently performed at least six times (A–D) and 11 times (E). **, P < 0.01; *, P < 0.05.JEM VOL. 206, August 31, 2009 
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cancer cells and MPs. Our results indicate that pancreatic 
and lung cancer cells are able to shed MPs expressing TF and 
PSGL­1 on their surface. In vivo, in a mouse model of cancer, 
these MPs circulate in the blood, accumulate at the site of injury 
in a P­selectin–dependent manner, and may participate in 
As previously described by others (Milsom et al., 2007; Pawlinski 
and Mackman, 2008), we observed that cancer cells express 
active TF, demonstrating activity ranging from 7 × 104 pmol/
cell for the two mouse cancer cell lines tested to 17 × 104 
pmol/cell for human SOJ­6 cancer cells (Fig. 7 D). All MPs 
studied expressed similar concentrations of active TF (between 
2.3 × 104 and 4.3 × 104 pmol/MP). We then determined 
the activity of TF as a ratio of TF concentration to surface area 
to control for the difference in size between a cancer cell (di­
ameter = 20 µm) and an MP (diameter = 1 µm). Results ob­
tained show that the density of active TF is increased >100­fold 
in MPs as compared with cancer cells. (Fig. 7 D). These cancer 
cell–derived MPs were able to activate platelets and to induce 
platelet aggregation and formation of a fibrin mesh after addi­
tion of platelet­poor plasma (PPP) to a washed platelet prepa­
ration (Fig. 7 E). This effect was slightly inhibited when a 
fibrinogen­deficient plasma was added to the platelet prepara­
tion and was abolished by using a factor VII–depleted PPP 
(Fig. 7 E). These data demonstrate that MPs activate and ag­
gregate platelets via a TF­dependent pathway in vitro.
To  determine  whether  endogenous  MPs  arising  from 
cancer cells accumulate in the thrombus growth via an inter­
action between PSGL­1 and P­selectin, the accumulation of 
endogenous Panc02­derived MPs was compared at the site   
of injury before and after infusion of a blocking P­selectin 
monoclonal antibody, as previously described (Falati et al., 
2003; Vandendries et al., 2007). Although accumulation of 
endogenous MPs was observed after laser­ or FeCl3­induced 
injury (Fig. 8 A, left) to the mesentery, no signal corresponding 
to endogenous cancer cell–derived MPs bound to a throm­
bus was detected upon infusion of the P­selectin antibody 
(Fig. 8 A, right). The same results were observed when exog­
enous  DiD­labeled  cancer  cell–derived  MPs  were  infused 
into the circulation in the presence of blocking antibody (un­
published data). We conclude that cancer cell–derived MPs 
accumulate at the site of thrombus formation via interactions 
between the PSGL­1 expressed at their surface and P­selectin 
expressed on activated platelets and endothelial cells. Further­
more, the median times to occlusion in arterioles (Fig. 8 B) 
and venules (Fig. 8 C) were significantly higher when cancer 
cell–derived MPs were infused in the presence of blocking 
P­selectin antibody than when they were infused alone (P < 
0.05). These results were confirmed by determining the tail 
bleeding time, which was significantly higher in the presence of 
P­selectin (P < 0.01; Fig. 8 D). Collectively, our results indicate 
that tumor­shed MPs reach the bloodstream, accumulate at the 
site of injury in a P­selectin­dependent manner, and accelerate 
thrombus growth mainly via a TF­dependent pathway.
DISCUSSION
In the present paper, we studied the role of cancer cell–derived 
MPs in thrombus formation. To characterize the throm­
botic/coagulation state in vivo, we measured the kinetics of 
thrombus formation after a chemical­ or laser­induced in­
jury. We also compared the tail bleeding time of healthy 
mice, mice developing tumors, and mice after infusion of 
Figure 6.  Endogenous cancer cell–derived MPs accumulate at the 
site of thrombus formation in vivo. (A) Qdot-labeled Panc02 cells (2 × 
106 cells) or Qdots alone (Control) were injected subcutaneously into the 
right flank of a mouse. 1 wk later, fluorescent signals were detected at the 
site of injection (left), and in the mesentery before (middle panel) and after 
(right) FeCl3-induced injury. (B) Fluorescence microscopy of Panc02 cells 
overexpressing GFP before subcutaneous injection into wild-type mice.  
(C and D) 2 × 105 Panc02 cells overexpressing GFP were injected subcuta-
neously into the right flank of a mouse. 5 wk later, the cremaster was iso-
lated and fluorescent circulating GFP-labeled MPs were detected in the 
blood microcirculation (red arrow, direction of the blood flow; red circle, 
GFP microparticle; C) and accumulating at the site of injury in venules  
(D, left) and arterioles (D, right). All images are representative of three 
independent experiments observed for nine thrombi formed in three mice.1922 A THROMBOTIC ROLE FOR CANCER MICROPARTICLES | Thomas et al.
cells to characterize their respective roles in the kinetics of 
thrombus formation in vivo.
Among the different proteins able to activate and aggre­
gate platelets while simultaneously favoring the process of 
metastasis, TF expressed on cancer cells has been suggested to 
play a key role in the development of a cancer­associated 
thrombotic state (Riewald and Ruf, 2001; Haas et al., 2006; 
the generation of thrombin, likely via the expression of ac­
tive TF at their surface. The presence of MPs is necessary for 
the formation of a thrombotic state in vivo. Finally, our re­
sults show that cancer cells do not accumulate at the site of 
injury and do not accelerate the kinetics of thrombosis in 
our model. To our knowledge, this is the first study to use 
imaging of endogenous cancer cell–derived MPs and cancer 
Figure 7.  Endogenous cancer-derived MPs accelerate thrombus growth through a TF-dependent pathway. (A–C) Kinetics of thrombosis in mice 
perfused with control Panc02 MPs or trypsinized Panc02 MPs (18,000 MPs/g/mouse) compared with wild-type mice. (A) Bleeding time of wild-type mice 
and of mice perfused with control MPs (WT+MPs) or trypsinized MPs (WT+trypsinized MPs; n = 6 mice for each group). Time to vessel occlusion reported 
in minutes for mesenteric arterioles (B) and venules (C; n = 6 thrombi in six mice for each group). Injury of the mesenteric vessels was induced by topical 
application of 10% FeCl3 for 5 min. Horizontal bars indicate median values. **, P < 0.01; *, P < 0.05. (D) Measurement of TF activity on the surface of can-
cer cells and MPs in pmol/cell1 and pmol/MP1 (left) or in pmol/mm2 (right), reported as the mean ± SD. (E) Aggregation of 2.5 × 108 human washed 
platelets/ml induced by addition of thrombin (Curve 1, red), SOJ-6 MPs (1 µg of MP-associated proteins/ml) in the absence (Curve 2, black) or presence of 
5% vol/vol (final) of PPP (Curve 3, blue), factor VII–depleted PPP (Curve 4, green), or fibrinogen-deficient PPP (Curve 5, gray). Experiments were indepen-
dently performed six times (A–C) and three times (D and E).JEM VOL. 206, August 31, 2009 
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Versteeg et al., 2008). However, no direct correlation could 
be established between the presence of TF on cancer cells and 
the development of thrombosis complications associated with 
cancer (Furie and Furie, 2006), suggesting that other impor­
tant mechanisms may link cancer and thrombosis. Recently, 
various reports have shown that the number of circulating 
MPs is increased in patients developing different types of can­
cers known to be associated with a thrombotic state (Kim et al., 
2003; Del Conde et al., 2007; Zwicker et al., 2007). These 
observations suggest that MPs may play a key role in the de­
velopment of the thrombotic complications associated with 
cancer. Our results indicate that MPs derived from cancer 
cells enhance thrombus formation. The presence of PSGL­1 
targets MPs to sites of thrombosis, whereas active TF actively 
participates in the formation of the thrombus by generating 
thrombin and fibrin. Two recent reports have shown, in mice 
models, a direct correlation between the size of a tumor and 
the level of TF present in cell­free plasma (Yu et al., 2005; 
Davila et al., 2008). We did not observe such correlation 
when comparing the bleeding time associated with the vol­
ume of the tumors (Fig. 5 E). Indeed, even relatively small 
tumors are sufficient enough to strongly diminish the tail 
bleeding time and the occlusion time in our model. These 
results confirm that the presence in the bloodstream of few 
tumor­derived MPs is sufficient enough to induce a throm­
botic state in mice. Last, in the two papers, authors have not 
discriminated the origin of circulating TF that may come 
from platelets or monocyte­derived MPs. Other studies have 
previously shown that such MPs may originate from platelets 
(Hron et al., 2007; Tesselaar et al., 2007). In this study, we 
observed that the quantities of circulating platelet­, endothe­
lial cell–, and cancer cell–derived MPs are increased in mice 
developing tumors compared with healthy mice. With the 
knowledge that platelets release MPs only when they aggre­
gate (Piccin et al., 2007), it not surprising that the amount of 
circulating MPs derived from platelets increases when patients/
mice develop a thrombotic state. Indeed, this pathological 
Figure 8.  Endogenous cancer-derived MPs accelerate thrombus 
formation in a P-selectin–dependent manner. (A) 2 × 105 Panc02 cells 
overexpressing GFP were injected subcutaneously into the right flank of a 
mouse. 5 wk later, chemical injury of the mesentery was induced, and 
fluorescence was detected in the absence (left, Control) or presence of 
circulating P-selectin blocking antibody (right, P-selectin antibody; n = 6 
thrombi in three mice). (B–D). Kinetics of thrombosis in wild-type mice, 
wild-type mice infused with Panc02 MPs (WT+MPs, 0.2 µg of MP-associ-
ated proteins/g/mouse), or with Panc02 MPs plus 2 µg/g/mouse of anti 
P-selectin blocking antibody (WT+MPs+anti P-sel). Controls were performed 
by infusion of anti–P-selectin antibody into wild-type mice (WT+anti  
P-sel) or by infusing an irrelevant antibody into wild-type mice perfused 
with MPs (WT+MPs+Irr Ab). Injury of the mesenteric vessels was chemi-
cally induced, and the time to vessel occlusion for arterioles (n = 10 for 
WT, n = 7 for WT+anti Psel, n = 10 for WT+MPs, n = 7 for WT+MPs+anti 
Psel, and n = 8 for WT+MPs+Irr Ab; B) and veinules (n = 13 for WT, n = 7 
for WT+anti Psel, n = 7 for WT+MPs, n = 7 for WT+MPs+anti Psel, and  
n = 8 for WT+MPs+Irr Ab; C) was measured. (D) Bleeding times were deter-
mined for all conditions studied (n = 13 for WT, n = 7 for WT+anti Psel,  
n = 8 for WT+MPs, n = 6 for WT+MPs+Anti Psel, and n = 8 for 
WT+MPs+Irr Ab). One thrombus was performed per mouse. Horizontal 
bars designate median values. Experiments were independently performed 
three times (A) and at least seven times (B–D). **, P < 0.01; *, P < 0.05.
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at least partially, by the levels of active TF expressed by 
Panc02­ and LLC1­derived MPs. Indeed, activation of the 
coagulation cascade resulting in thrombin generation is known 
to play a more important role in thrombus formation induced 
in arteries than in veins.
We demonstrated that PSGL­1 is present on the surface of 
MPs and showed that injection of a P­selectin blocking anti­
body prevents the accumulation of MPs at the site of injury 
and reduces thrombus formation. The P­selectin–PSGL­1 
axis has previously been described as being involved in the 
binding of MPs to platelets. Indeed, Falati et al. (2003) have 
previously shown that exogenous monocyte­derived MPs ex­
press PSGL­1 and bind to a growing thrombus in a P­selectin–
dependent manner in a laser injury model. We determined 
that inhibition of P­selectin did not affect time to occlusion 
in the FeCl3 model in healthy mice, showing that accumula­
tion of monocyte­derived MPs by the P­selectin–PSGL­1 
axis may have a minor implication when cancer­derived MPs 
are not involved in thrombus formation after a FeCl3­induced 
injury. Our results identify P­selectin as a potentially good 
pharmaceutical target for the prevention of thrombosis asso­
ciated with cancer, and may also explain why heparin, which 
binds to and blocks selectin, is much more effective than war­
farin, a vitamin K antagonist, in preventing thrombosis in pa­
tients suffering from Trousseau’s syndrome (Del Conde et al., 
2007). MPs also express negatively charged phospholipids on 
their surface that may participate with TF in activation of the 
coagulation cascade. However, based on our results, the ac­
tivity of TF seems to be critical for the generation of throm­
bin. Indeed, we found that (a) in vitro TF activity per surface 
unit is 100­fold more important in MPs than in their parental 
cells (Fig. 7 D), (b) the use of factor VII–deficient plasma 
abolishes the effect of MPs on platelet aggregation and the 
formation of a fibrin mesh (Fig. 7 E), and (c) in vivo hydroly­
sis of the surface proteins but not the negatively charged phos­
pholipids present on MPs completely abrogated their effect 
on the kinetics of thrombosis (Fig. 7, A–C). Based on our re­
sults, we propose a two­step mechanism to describe the in­
volvement of cancer cell–derived MPs in thrombosis. First, 
MPs bind to the site of injury by interactions between PSGL­1 
and P­selectin present on activated platelets and endothelial 
cells. Second, MPs affect thrombus formation, likely via the 
expression of active TF on their surface. Other proteins and 
lipids may also be of importance in this process. Among the 
different proteins expressed by cancer cell–derived MPs, feto­
acinar pancreatic protein and fibronectin were identified (un­
published data; Ni et al., 2003). Both of these may play an 
important role in thrombus formation. Fetoacinar pancreatic 
protein, an onco­isoform of bile salt–dependent lipase, increases 
the kinetics of thrombus formation by binding to CXCR4 
on the surface of activated platelets (Panicot­Dubois et al., 
2007). Overall, our data provide a new molecular basis for es­
tablishing relationships between cancer and thrombosis, and 
may facilitate the development of new pharmaceutical drugs 
designed to prevent thrombosis and metastasis in patients suf­
fering from cancer.
state leads to the activation and aggregation of platelets, either 
directly via cancer cells or indirectly via production of throm­
bin by TF. Therefore, it is likely that platelet­derived MPs are 
a consequence of thrombotic complications and do not cause 
the development of this phenotype. However, platelet­
derived MPs, when present in the blood, may also participate   
in the stability of a thrombotic state associated with cancer. 
Endothelial cells activated by tumoral MPs may provide a sup­
plementary procoagulant surface by TF exposure. Although 
several reports have shown that TF is expressed on cancer cells, 
there is conflicting evidence as to the presence of this factor 
at the surface of platelets and their MPs (Furie and Furie, 
2006). To our knowledge, this is the first paper to demon­
strate an increase in circulating endothelial cell–derived MPs 
in association with cancer. However, previous publications 
have shown that the level of endothelial cell–derived MPs is 
increased in inflammatory­related diseases (Combes et al., 1999; 
Chamouard et al., 2005). These MPs, by expressing proteins 
such as metalloproteases, urokinase plasminogen activator, 
and urokinase plasminogen activator receptor (Lacroix et al., 
2007), may potentially take part in and amplify the processes 
of inflammation, angiogenesis, and fibrinolysis. Further ex­
periments are needed to determine the actual role of platelet­
derived MPs in concert with cancer cell– and endothelial 
cell–derived MPs.
When cancer cells and cancer cell–derived MPs were 
infused into the circulation of a living mouse, only MPs 
were observed to accumulate at the site of a laser­ or chemi­
cal­induced injury, suggesting that cancer cells may not 
participate in thrombus formation. These cells were not 
eliminated from the blood, because we were able to detect 
them circulating in the vessels (Fig. 4 C, before injury). This 
result was confirmed by our data showing that injection of 
cancer cells did not influence either the kinetics of throm­
bus formation or bleeding times. Our results are consistent 
with previous observations showing that monocyte­derived 
MPs, but not their parent cells, may indeed interact with a 
growing thrombus (Falati et al., 2003). Although circulating 
cancer cells did not bind to the site of injury, they may in­
teract with the endothelium at sites of premetastatic niches 
to form sites of metastasis (Kaplan et al., 2006). Different 
hypotheses may explain why MPs and not their parental 
cells bind to a growing thrombus. It is possible that this 
interaction occurs via the negative phospholipid moieties 
commonly expressed on the surface of MPs. Furthermore, 
the quantity and density of binding partners present, such as 
PSGL­1, may be more important for MPs than for their par­
ent cells. This point is illustrated by our results showing that 
even if the activity of cell TF was greater than that of the 
MP, when the results were reported per surface unit, the 
activity of TF was >100­fold higher in MPs than in cells. 
This result may also explain why the cells were not throm­
bogenic compared with MPs. In our conditions, Panc02­
derived MPs have a more dramatic effect on thrombosis in 
arterioles compared with venules, whereas LLC1­derived 
MPs have the opposite effect. This tendency may be caused, JEM VOL. 206, August 31, 2009 
ARTICLE
1925
as previously described (Dignat­George, 2006). L929 and J774 cells were ac­
tivated with 10 ng/ml TNF­ before MP isolation. Concentrations of MPs 
were determined by protein quantification using the bicinchoninic acid assay 
(Thermo Fisher Scientific).
PAGE and Western blotting. SDS­PAGE performed on gels of poly­
acrylamide (7.5% acrylamide in the presence of 0.1% sodium dodecyl sulfate) 
and Western blotting were performed as previously described (Panicot­Dubois 
et al., 2007).
Flow cytometry. Platelet­free plasma (PFP) samples were prepared as pre­
viously described (Sabatier et al., 2002) using serial centrifugations and stored 
at 80°C until use. For MP labeling, 30 µl of freshly thawed PFP or of the 
MP suspension was incubated for 30 min with 10 µl FITC–annexin V or 
PE–anti–mouse  monoclonal  antibodies  (30  µg/ml  anti­CD41,  40  µg/ml 
anti–TER­119, 40 µg/ml anti­CD45, 40 µg/ml anti­CD31, or 50 µg/ml 
anti–PSGL­1). Concentration­matched PE­isotype antibodies (IgG1, clone 
R3­34; IgG2a, clone R35­95; IgG2b, clone A95­1) or annexin V–FITC 
with phosphate­buffered saline without calcium were used as control. Analy­
ses were performed on a flow cytometer (Cytomics FC500; Beckman Coul­
ter) using a Megamix bead–calibrated protocol (BioCytex), as previously 
described (Robert et al., 2009). Flow­Count fluorospheres (Beckman Coul­
ter) were added to each sample to express MP counts as absolute numbers.
Fluorescence microscopy. Cells were grown up to 80% confluence on an 
8­chamber glass slide system (Thermo Fisher Scientific), washed with PBS, 
and fixed for 30 min at 4°C in PBS containing 2% paraformaldehyde. Once 
fixed, cells were blocked for 1 h at 4°C with 1% BSA in PBS buffer. Cells 
were then incubated at 4°C with the appropriate dilution of antibodies, fol­
lowed by incubation with an Alexa Fluor 488– or Alexa Fluor 594–conjugated 
secondary antibody. Between each step, cells were exhaustively rinsed with 
PBS and were observed on a microscope (Axiovert 200; Carl Zeiss, Inc.).
TF activity assays. A chromogenic assay (Actichrome TF; American Diag­
nostica Inc.) was used to analyze TF activity. TF activity was measured in cell 
or MP suspension according to the manufacturer’s instructions. Cells or MPs 
were incubated in the presence of factors VIIa and X. The reagents were in­
cubated at 37°C for complex formation to convert factor X to factor Xa, and 
the amount of Xa generated was measured by its ability to cleave a chromo­
genic substrate, spectrozyme Xa. Absorbance was read at 405 nm with a mi­
croplate reader (MR5000; Dynatech). TF concentration was determined by 
interpolation of a standard curve obtained from different amounts of lipidated 
TF standards. For TF activity measurement in mouse plasma, a TF/TF path­
way inhibitor–depleted plasma was added to the reaction mixture of lipidated 
TF standards, and A405–490 was measured to calculate TF concentration.
Platelet aggregation studies. Washed platelets were obtained as previ­
ously described (Dubois et al., 2004). 2.5 × 108 washed platelets/ml were 
stirred at 37°C for 10 min in 2 × 4­channel aggregometers (Apact 4004; 
LABiTec). Positive controls were performed in the presence of 1 U/ml 
thrombin. The extent of platelet aggregation was defined as the percent 
change in optical density (Dubois et al., 2007).
MP half-life. The carotid arteries and jugular veins of 8­wk­old mice were 
cannulated. DiO­labeled MPs were infused in the bloodstream via the jugu­
lar veins. Blood samples were collected in sodium citrate (3.2%, 1:2 vol/vol) 
via the carotid artery catheter before MP injection and 5, 15, 30, 45, and 60 
min after injection.
Induction of ectopic tumor. For all in vivo experiments, tumor cells in 
the exponential growth phase were briefly exposed to nonenzymatic cell dis­
sociation buffer to dislodge the cells. They were next carefully washed, resus­
pended in PBS, and diluted to the desired cell number/inoculum. 3­wk­old 
C57BL/6 mice were injected subcutaneously into the right flank with 2 × 
105 Panc02 cells, 2 × 105 LLC1 cells, 2 × 106 Panc02­labeled cells, or with 
MATERIALS AND METHODS
Mice. Wild­type C57BL/6J mice were obtained from Janvier. All animal 
care and experimental procedures were performed as recommended by the 
European Community guidelines and approved by the local ethical commit­
tee of the Université de la Méditerranée and the French Ministry of Agricul­
ture (agreement no. 13.382).
Antibodies and reagents. Rat monoclonal anti–mouse CD41 antibody 
(clone MWReg30) was obtained from Emfret. Fab fragments for the anti­
CD41 antibody were generated by using the immunopure Fab preparation 
kit from Thermo Fisher Scientific, and then conjugated to Alexa Fluor 660. 
Human ­thrombin, factor VII–deficient plasma, and sheep anti–human TF 
were obtained from Biopep. Rabbit anti–mouse TF was purchased from 
American Diagnostica Inc. PE rat anti–mouse CD41 (clone MWReg30), 
PE rat anti–mouse CD45 (clone 30­F11), PE rat anti–mouse CD31 (clone 
MEC 13.3), PE rat anti–mouse TER­119 (clone TER­119), PE rat anti–
mouse  PSGL­1,  blocking  rat  monoclonal  anti–mouse  P­selectin  (clone 
RB40.34), and rat monoclonal anti–mouse PSGL­1 (clone 4RA10) anti­
bodies, and FITC–annexin V, PE–annexin V, and PE rat and mouse isotype 
controls were obtained from BD. Monoclonal anti­CA19.9 and anti–MUC­
1–core  glycoprotein  antibodies  were  purchased  from  Novocastra  Labo­
ratories and were conjugated in house to Alexa Fluor 488. Irrelevant rat 
immunoglobulins were purchased from BD and SouthernBiotech. Peroxy­
dase­conjugated donkey anti–rat, donkey anti–rat–Alexa Fluor 488, donkey 
anti–sheep–Alexa Fluor 488, and donkey anti–rabbit–Alexa Fluor 594 anti­
bodies; Vybrant DiD and DiO cell­labeling solutions; the Qtracker 705 cell 
labeling kit; Alexa Fluor 594 and Alexa Fluor 660 antibody­labeling kits; 
Syto 62, Lipofectamine 2000, PLUS reagent, RPMI 1640, DMEM, and 
OptiMEM media; and penicillin, streptomycin, l­glutamine, trypsin­EDTA, 
nonenzymatic cell dissociation solution, and fungizone were obtained from 
Invitrogen. Megamix beads were purchased from BioCytex. Prostaglandin 
I2 was obtained from EMD. BSA, apyrase grade VI, Gly­Pro­Arg­Pro, and 
FeCl3 were purchased from Sigma­Aldrich. pEGFP­N1 vector was obtained 
from Clontech Laboratories, Inc. Tirofiban (Aggrastat) was purchased from 
Iroko Pharmaceuticals.
Cell lines and culture conditions. One cell line from human pancreatic 
adenocarcinomas (SOJ­6; Fujii et al., 1990), and two cell lines from a mouse 
pancreatic adenocarcinoma (Panc02) and a Lewis lung carcinoma (LLC1) 
were studied. The Panc02 cell line has been established and described by 
Corbett et al. (1984). In brief, it is derived from a pancreatic ductal adeno­
carcinoma induced by implantation of cotton thread–carrying 3­methyl­
cholanthrene into the pancreas tissue of a C57BL/6 mouse. The LLC1 cell 
line has been established and described by Bertram and Janik (1980) and was 
obtained from the American Type Culture Collection. It is derived from a 
Lewis lung carcinoma of a C57BL mouse strain. The Panc02 cell line was 
provided by E. Beraud (Institut National de la Santé et de la Recherche 
Médicale [INSERM] UMR911, Marseille, France). L929 mouse fibroblasts 
and J774 mouse macrophages were provided by F. Levy (INSERM UMR608, 
Marseille, France). SOJ­6, LLC1, L929, and J774 cells were grown in DMEM 
medium, and Panc02 cells were grown in RPMI 1640 medium. Media were 
supplemented with 10% FCS, 2 mM l­glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 0.1% fungizone. Cells were grown at 37°C in a 
humidified atmosphere with 5% CO2.
Transfection. Panc02 cells were stably transfected with the pEGFP­N1 
plasmid using Lipofectamine 2000 and PLUS reagent according to the man­
ufacturer’s recommendations. Cells were cloned as previously described 
(Panicot­Dubois et al., 2004).
Isolation of MPs. The isolation of MPs was adapted from Berckmans et al. 
(2001). In brief, cells at 80% of confluency were incubated for 15 h in Op­
tiMEM medium. MP­rich medium was centrifuged at 1,500 g to eliminate 
cellular debris and ultracentrifuged at 20,000 g to isolate MPs. The final pel­
let containing MPs was resuspended in 0.5 ml PBS. Mice MPs were isolated 1926 A THROMBOTIC ROLE FOR CANCER MICROPARTICLES | Thomas et al.
humans and support low grade thrombin generation. Thromb. Haemost. 
85:639–646.
Bertram, J.S., and P. Janik. 1980. Establishment of a cloned line of Lewis 
Lung Carcinoma cells adapted to cell culture. Cancer Lett. 11:63–73. 
Blom, J.W., S. Osanto, and F.R. Rosendaal. 2006a. High risk of venous 
thrombosis in patients with pancreatic cancer: a cohort study of 202 
patients. Eur. J. Cancer. 42:410–414. 
Blom, J.W., J.P. Vanderschoot, M.J. Oostindiër, S. Osanto, F.J. van der 
Meer, and F.R. Rosendaal. 2006b. Incidence of venous thrombosis in a 
large cohort of 66,329 cancer patients: results of a record linkage study. 
J. Thromb. Haemost. 4:529–535. 
Chamouard, P., D. Desprez, B. Hugel, C. Kunzelmann, C. Gidon­Jeangirard, 
M. Lessard, R. Baumann, J.M. Freyssinet, and L. Grunebaum. 2005. 
Circulating cell­derived microparticles in Crohn’s disease. Dig. Dis. Sci. 
50:574–580. 
Combes, V., A.C. Simon, G.E. Grau, D. Arnoux, L. Camoin, F. Sabatier, M. 
Mutin, M. Sanmarco, J. Sampol, and F. Dignat­George. 1999. In vitro 
generation of endothelial microparticles and possible prothrombotic ac­
tivity in patients with lupus anticoagulant. J. Clin. Invest. 104:93–102. 
Corbett, T.H., B.J. Roberts, W.R. Leopold, J.C. Peckham, L.J. Wilkoff, 
D.P. Griswold Jr., and F.M. Schabel Jr. 1984. Induction and chemo­
therapeutic response of two transplantable ductal adenocarcinomas of 
the pancreas in C57BL/6 mice. Cancer Res. 44:717–726.
Davila, M., A. Amirkhosravi, E. Coll, H. Desai, L. Robles, J. Colon, C.H. 
Baker, and J.L. Francis. 2008. Tissue factor­bearing microparticles de­
rived from tumor cells: impact on coagulation activation. J. Thromb. 
Haemost. 6:1517–1524.
Del Conde, I., L.D. Bharwani, D.J. Dietzen, U. Pendurthi, P. Thiagarajan, 
and J.A. López. 2007. Microvesicle­associated tissue factor and Trousseau’s 
syndrome. J. Thromb. Haemost. 5:70–74. 
Dignat­George, F. 2006. Detection of circulating endothelial cells and en­
dothelial progenitor cells by flow cytometry. Cytometry B Clin. Cytom. 
70:104–105.
Dubois, C., B. Steiner, and S.C. Meyer Reigner. 2004. Contribution of 
PAR­1, PAR­4 and GPIbalpha in intracellular signaling leading to the 
cleavage of the beta3 cytoplasmic domain during thrombin­induced 
platelet aggregation. Thromb. Haemost. 91:733–742.
Dubois, C., B. Atkinson, B.C. Furie, and B. Furie. 2006a. Real time in 
vivo imaging of platelets during thrombus formation. In Platelets. A.D. 
Michelson, editor. Elsevier/Academic Press, Worcester, MA. 611–628.
Dubois,  C.,  L.  Panicot­Dubois,  G.  Merrill­Skoloff,  B.  Furie,  and  B.C. 
Furie. 2006b. Glycoprotein VI­dependent and ­independent pathways 
of thrombus formation in vivo. Blood. 107:3902–3906. 
Dubois, C., L. Panicot­Dubois, J.F. Gainor, B.C. Furie, and B. Furie. 2007. 
Thrombin­initiated platelet activation in vivo is vWF independent during 
thrombus formation in a laser injury model. J. Clin. Invest. 117:953–960. 
Dvorak, H.F., S.C. Quay, N.S. Orenstein, A.M. Dvorak, P. Hahn, A.M. 
Bitzer, and A.C. Carvalho. 1981. Tumor shedding and coagulation. 
Science. 212:923–924. 
Falati, S., Q. Liu, P. Gross, G. Merrill­Skoloff, J. Chou, E. Vandendries, A. 
Celi, K. Croce, B.C. Furie, and B. Furie. 2003. Accumulation of tissue 
factor into developing thrombi in vivo is dependent upon microparticle 
P­selectin glycoprotein ligand 1 and platelet P­selectin. J. Exp. Med. 
197:1585–1598. 
Fujii, Y., M. Sekiguchi, Y. Shiroko, H. Shimizu, I. Sugawara, K. Hasumi, M. 
Eriguchi, T. Ikeuchi, and H. Uchida. 1990. Establishment and characteriza­
tion of human pancreatic adenocarcinoma cell line SOJ producing carcino­
embryonic antigen and carbohydrate antigen 19­9. Hum. Cell. 3:31–36.
Furie, B., and B.C. Furie. 2006. Cancer­associated thrombosis. Blood Cells 
Mol. Dis. 36:177–181. 
Gasic, G.J., P.A. Koch, B. Hsu, T.B. Gasic, and S. Niewiarowski. 1976. 
Thrombogenic activity of mouse and human tumors: effects on plate­
lets, coagulation, and fibrinolysis, and possible significance for metasta­
ses. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 86:263–277. 
Ghosh, A., W. Li, M. Febbraio, R.G. Espinola, K.R. McCrae, E. Cockrell, 
and R.L. Silverstein. 2008. Platelet CD36 mediates interactions with 
endothelial cell­derived microparticles and contributes to thrombosis in 
mice. J. Clin. Invest. 118:1934–1943.
PBS alone for control mice. Cells were labeled with Qdots (Qtraker 705), 
DiD, or DiO according to the manufacturer’s instructions (Invitrogen).
Intravital microscopy. Mice were anesthetized with an intraperitoneal in­
jection of 100 mg/kg ketamine and 12.5 mg/kg Xylazine (Bayer). The jugu­
lar vein was cannulated to maintain anesthesia by injection of 50 mg/kg 
pentobarbital injection and to infuse antibodies, cells, and MPs as needed. The 
trachea was intubated to facilitate spontaneous respiration by the mouse, and 
a thermocontrolled blanket maintained the mouse at 37°C. Cremaster and 
mesentery preparations were performed as previously described by Dubois   
et al. (2007). Intravital videomicroscopy was performed as previously de­
scribed (Dubois et al., 2007; Panicot­Dubois et al., 2007). Data were obtained 
using a microscope (BX61WI; Olympus) with a 60 × 0.9 or a 20 × 0.5 NA water 
immersion objective. Alternatively, a fibered fluorescence microscopy imag­
ing system (Cellvizio; Mauna Kea Technologies) was used to image platelets. 
The optical probe used in this study has a tip diameter of 4.2 mm (MiniO/100; 
Mauna Kea Technologies), providing images below the surface of biological 
tissue and at a depth 100 ± 5 µm, with a lateral resolution of 1.8 µm.
FeCl3-induced injury. The FeCl3­induced model of thrombosis has been 
shown to cause substantial damage to the endothelium and exposure of un­
derlying collagen (Dubois et al., 2006b). Vessel injuries were generated by us­
ing a 1 × 2–mm filter paper soaked with a 10% FeCl3 solution and placed over 
the vessel for 5 min, as previously described (Dubois et al., 2006b). Platelet 
accumulation at the site of injury was detected by infusion in blood circula­
tion of 250 ng/g/mouse of anti­CD41 Fab fragment coupled with Alexa 
Fluor 660 for 35 min or until blood flow cessation lasted for >10 s (occlusion). 
Typically, one venous and one arterial injury were performed per mouse.
Laser-induced injury. Vessel­wall injuries were induced with a nitrogen 
dye laser (Micropoint; Photonics Instruments) focused through the micro­
scope objective, parfocal with the focal plane and aimed at the vessel wall, as 
previously described (Dubois et al., 2006b; Dubois et al., 2007). Typically, 
one or two pulses were required to induce vessel wall injury.
Tail bleeding time. Tail bleeding times were performed as previously de­
scribed on anesthetized 8­wk­old mice (Dubois et al., 2007).
Statistics. Significance was determined by a paired two­tailed Student’s   
t test for the in vitro experiments and by Wilcoxon’s rank­sum test for the in 
vivo experiments. The difference was considered significant at P < 0.05.
Online supplemental material. Fig. S1 shows the box plot distribution of 
CD31+CD41 MPs and TER119+ MPs in healthy and tumor­bearing mice 
(data are from Table I). Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082297/DC1.
The authors are indebted to L. Arnaud for the quantification of MPs. The authors are 
grateful to J. Varin, J. Courageot, and C. Prévot for expert technical assistance, and 
to M.-C. Alessi for the use of the aggregometers. The authors thank P.-A. Dancer,  
B. Brisson, J. Rebouillat, A. Hembury, and Mauna Kea Technologies for the use of the 
Cellvizio fibered fluorescence microscopy imaging system.
This work was supported by institutional funding from INSERM and Aix-
Marseille Université. This work was supported by the Association pour la Recherche 
sur le Cancer (grant ARC-1038 to C. Dubois).
The authors have no conflicting financial interests.
Submitted: 14 October 2008
Accepted: 17 July 2009
REFERENCES
Abid  Hussein,  M.N.,  E.W.  Meesters,  N.  Osmanovic,  F.P.  Romijn,  R. 
Nieuwland, and A. Sturk. 2003. Antigenic characterization of endothelial 
cell­derived microparticles and their detection ex vivo. J. Thromb. Haemost. 
1:2434–2443. 
Berckmans, R.J., R. Neiuwland, A.N. Böing, F.P. Romijn, C.E. Hack, 
and A. Sturk. 2001. Cell­derived microparticles circulate in healthy JEM VOL. 206, August 31, 2009 
ARTICLE
1927
CXCR4 and modulates thrombus formation in mice and humans.  
J. Clin. Invest. 117:3708–3719. 
Pawlinski, R., and N. Mackman. 2008. Use of mouse models to study the role 
of tissue factor in tumor biology. Semin. Thromb. Hemost. 34:182–186. 
Piccin, A., W.G. Murphy, and O.P. Smith. 2007. Circulating microparti­
cles: pathophysiology and clinical implications. Blood Rev. 21:157–171. 
Prandoni, P., A.W. Lensing, H.R. Büller, A. Cogo, M.H. Prins, A.M. 
Cattelan, S. Cuppini, F. Noventa, and J.W. ten Cate. 1992. Deep­vein 
thrombosis  and  the  incidence  of  subsequent  symptomatic  cancer.  
N. Engl. J. Med. 327:1128–1133.
Riewald, M., and W. Ruf. 2001. Mechanistic coupling of protease signaling 
and initiation of coagulation by tissue factor. Proc. Natl. Acad. Sci. USA. 
98:7742–7747. 
Robert, S., P. Poncelet, R. Lacroix, L. Arnaud, L. Giraudo, A. Hauchard, 
J. Sampol, and F. Dignat­George. 2009. Standardization of platelet­
derived microparticle counting using calibrated beads and a Cytomics 
FC500 routine flow cytometer: a first step towards multicenter studies? 
J. Thromb. Haemost. 7:190–197. 
Sabatier, F., P. Darmon, B. Hugel, V. Combes, M. Sanmarco, J.G. Velut, 
D. Arnoux, P. Charpiot, J.M. Freyssinet, C. Oliver, et al. 2002. Type 
1 and type 2 diabetic patients display different patterns of cellular mic­
roparticles. Diabetes. 51:2840–2845. 
Sack, G.H., Jr., J. Levin, and W.R. Bell. 1977. Trousseau’s syndrome and 
other manifestations of chronic disseminated coagulopathy in patients 
with  neoplasms:  clinical,  pathophysiologic,  and  therapeutic  features. 
Medicine (Baltimore). 56:1–37. 
Schiavetti, A., M. Foco, A. Ingrosso, E. Bonci, L. Conti, and M. Matrunola. 
2008. Venous thrombosis in children with solid tumors. J. Pediatr. Hematol. 
Oncol. 30:148–152. 
Sierko, E., and M.Z. Wojtukiewicz. 2007. Inhibition of platelet function: does 
it offer a chance of better cancer progression control? Semin. Thromb. 
Hemost. 33:712–721. 
Stein, P.D., A. Beemath, F.A. Meyers, E. Skaf, J. Sanchez, and R.E. Olson. 
2006. Incidence of venous thromboembolism in patients hospitalized with 
cancer. Am. J. Med. 119:60–68. 
Tesselaar, M.E., F.P. Romijn, I.K. Van Der Linden, F.A. Prins, R.M. Bertina, 
and S. Osanto. 2007. Microparticle­associated tissue factor activity: a link 
between cancer and thrombosis? J. Thromb. Haemost. 5:520–527. 
Tilley, R.E., T. Holscher, R. Belani, J. Nieva, and N. Mackman. 2008. 
Tissue factor activity is increased in a combined platelet and micropar­
ticle sample from cancer patients. Thromb. Res. 122:604–609.
Trousseau,  A.  1865.  Phlegmasia  alba  dolens.  In  Clinique  Médicale  de 
l’Hôtel­Dieu. J.­B. Baillière, Paris. 654–712.
Vandendries, E.R., J.R. Hamilton, S.R. Coughlin, B. Furie, and B.C. Furie. 
2007. Par4 is required for platelet thrombus propagation but not fibrin 
generation in a mouse model of thrombosis. Proc. Natl. Acad. Sci. USA. 
104:288–292. 
Versteeg, H.H., F. Schaffner, M. Kerver, H.H. Petersen, J. Ahamed, B. Felding­
Habermann, Y. Takada, B.M. Mueller, and W. Ruf. 2008. Inhibition of 
tissue factor signaling suppresses tumor growth. Blood. 111:190–199. 
Willekens, F.L., J.M. Werre, J.K. Kruijt, B. Roerdinkholder­Stoelwinder, Y.A. 
Groenen­Döpp, A.G. van den Bos, G.J. Bosman, and T.J. van Berkel. 
2005. Liver Kupffer cells rapidly remove red blood cell­derived vesicles 
from the circulation by scavenger receptors. Blood. 105:2141–2145. 
Yu, J.L., L. May, V. Lhotak, S. Shahrzad, S. Shirasawa, J.I. Weitz, B.L. 
Coomber, N. Mackman, and J.W. Rak. 2005. Oncogenic events regu­
late tissue factor expression in colorectal cancer cells: implications for 
tumor progression and angiogenesis. Blood. 105:1734–1741. 
Zwicker, J.I., B.C. Furie, and B. Furie. 2007. Cancer­associated thrombosis. 
Crit. Rev. Oncol. Hematol. 62:126–136. 
Haas, S.L., R. Jesnowski, M. Steiner, F. Hummel, J. Ringel, C. Burstein, 
H. Nizze, S. Liebe, and J.M. Löhr. 2006. Expression of tissue factor in 
pancreatic adenocarcinoma is associated with activation of coagulation. 
World J. Gastroenterol. 12:4843–4849.
Hron, G., M. Kollars, H. Weber, V. Sagaster, P. Quehenberger, S. Eichinger, 
P.A. Kyrle, and A. Weltermann. 2007. Tissue factor­positive micropar­
ticles: cellular origin and association with coagulation activation in pa­
tients with colorectal cancer. Thromb. Haemost. 97:119–123.
Kakkar, A.K., and R.C. Williamson. 1999. Prevention of venous thrombo­
embolism in cancer patients. Semin. Thromb. Hemost. 25:239–243. 
Kaplan, R.N., S. Rafii, and D. Lyden. 2006. Preparing the “soil”: the pre­
metastatic niche. Cancer Res. 66:11089–11093. 
Khorana, A.A., S.A. Ahrendt, C.K. Ryan, C.W. Francis, R.H. Hruban, Y.C. 
Hu, G. Hostetter, J. Harvey, and M.B. Taubman. 2007. Tissue factor ex­
pression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer 
Res. 13:2870–2875. 
Kim, H.K., K.S. Song, Y.S. Park, Y.H. Kang, Y.J. Lee, K.R. Lee, H.K. 
Kim, K.W. Ryu, J.M. Bae, and S. Kim. 2003. Elevated levels of cir­
culating platelet microparticles, VEGF, IL­6 and RANTES in patients 
with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer. 
39:184–191. 
Lacroix, R., F. Sabatier, A. Mialhe, A. Basire, R. Pannell, H. Borghi, S. 
Robert, E. Lamy, L. Plawinski, L. Camoin­Jau, et al. 2007. Activation 
of plasminogen into plasmin at the surface of endothelial microparticles: 
a mechanism that modulates angiogenic properties of endothelial pro­
genitor cells in vitro. Blood. 110:2432–2439. 
Langer, F., B. Spath, K. Haubold, K. Holstein, G. Marx, J. Wierecky, T.H. 
Brümmendorf, J. Dierlamm, C. Bokemeyer, and B. Eifrig. 2008. Tissue 
factor procoagulant activity of plasma microparticles in patients with 
cancer­associated disseminated intravascular coagulation. Ann. Hematol. 
87:451–457. 
Milsom, C., J. Yu, L. May, B. Meehan, N. Magnus, K. Al­Nedawi, J. 
Luyendyk, J. Weitz, P. Klement, G. Broze, et al. 2007. The role of 
tumor­and host­related tissue factor pools in oncogene­driven tumor 
progression. Thromb. Res. 120(Suppl. 2):S82–S91. 
Müller, I., A. Klocke, M. Alex, M. Kotzsch, T. Luther, E. Morgenstern, S. 
Zieseniss, S. Zahler, K. Preissner, and B. Engelmann. 2003. Intravascular 
tissue factor initiates coagulation via circulating microvesicles and plate­
lets. FASEB J. 17:476–478.
Myers, D.D., A.E. Hawley, D.M. Farris, S.K. Wrobleski, P. Thanaporn, 
R.G. Schaub, D.D. Wagner, A. Kumar, and T.W. Wakefield. 2003. 
P­selectin and leukocyte microparticles are associated with venous 
thrombogenesis. J. Vasc. Surg. 38:1075–1089. 
Neoptolemos, J.P., D.D. Stocken, J.A. Dunn, J. Almond, H.G. Beger, P. 
Pederzoli, C. Bassi, C. Dervenis, L. Fernandez­Cruz, F. Lacaine, et al; 
European Study Group for Pancreatic Cancer. 2001. Influence of resec­
tion margins on survival for patients with pancreatic cancer treated by 
adjuvant chemoradiation and/or chemotherapy in the ESPAC­1 ran­
domized controlled trial. Ann. Surg. 234:758–768. 
Ni, H., P.S. Yuen, J.M. Papalia, J.E. Trevithick, T. Sakai, R. Fässler, R.O. 
Hynes, and D.D. Wagner. 2003. Plasma fibronectin promotes thrombus 
growth and stability in injured arterioles. Proc. Natl. Acad. Sci. USA. 
100:2415–2419. 
Panicot­Dubois, L., M. Aubert, C. Franceschi, E. Mas, F. Silvy, C. Crotte, 
J.P. Bernard, D. Lombardo, and M.O. Sadoulet. 2004. Monoclonal an­
tibody 16D10 to the C­terminal domain of the feto­acinar pancreatic 
protein binds to membrane of human pancreatic tumoral SOJ­6 cells 
and inhibits the growth of tumor xenografts. Neoplasia. 6:713–724. 
Panicot­Dubois, L., G.M. Thomas, B.C. Furie, B. Furie, D. Lombardo, 
and C. Dubois. 2007. Bile salt­dependent lipase interacts with platelet 